Edesa Biotech
Open
$5.85
Prev. Close
$5.85
High
$5.89
Low
$5.81
Market Snapshot
$48.42M
-4.6
-1.87
17
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. The company is headquartered in Markham, Ontario and currently employs 17 full-time employees. The company went IPO on 2008-08-25. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. The company is headquartered in Markham, Ontario and currently employs 17 full-time employees. The company went IPO on 2008-08-25. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Recently from Cashu
Please provide the content you want summarized, and I'll help you with a title.
It seems you haven't provided the content you'd like summarized. Please share the relevant text, and I'll assist you in creating the summary as requested.
Request for Content Details to Summarize Edesa Biotech Developments.
It appears there was a misunderstanding as I do not have access to the specific content you're referring to for summarization. If you could kindly provide the text or details regarding Edesa Biotech’s…
Edesa Biotech Advances Phase 2 Trials for Innovative Atopic Dermatitis Treatment
Edesa Biotech Advances in Clinical Trials for Skin Disorders Edesa Biotech takes a significant step forward by advancing its clinical trials focused on a groundbreaking treatment for skin disorders. T…
Edesa Biotech Enhances Localized Drug Delivery for Targeted Dermatologic Treatment and Patient Care.
Edesa Biotech Advances Localized Drug Delivery Technology Edesa Biotech, a clinical-stage biopharmaceutical company, focuses on developing innovative treatments for skin diseases and wound healing. Re…